OncoZenge AB (DE:8LY)

FRANKFURT:8LY

8LY

OncoZenge AB

RESEARCH TOOLSreports

OncoZenge AB (8LY) Price & Analysis

0 Followers

8LY Stock Chart & Stats

€0.59

-€0.02(-7.82%)

At close: Jan 08 4:00 PM EST

€0.59

-€0.02(-7.82%)

Day’s Range― - ―

52-Week Range€0.45 - €0.75

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€9.64M

Enterprise Value€112.91M

Total Cash (Recent Filing)€935.00K

Total Debt (Recent Filing)€7.50M

Price to Earnings (P/E)―

Beta0.51

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.74

Shares Outstanding14,048,068

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)-139.70

Price to Sales (P/S)30.78

P/FCF Ratio-6.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.09

Revenue Forecast (FY)€924.04K

Bulls Say, Bears Say

Bulls Say

Clear Commercial PathwayOncoZenge’s business is organized around a single, well‑defined product candidate (BupiZenge) with an explicit commercialization route (product sales, licensing, royalties). That focused asset strategy simplifies resource allocation, partner negotiations and clinical prioritization over coming months.

Positive Product‑level EconomicsReported positive TTM gross profit indicates the product formulation can generate unit‑level margin. If BupiZenge reaches approval or partnering, positive gross economics provide a structural foundation to scale revenue without every dollar turning into loss, supporting longer‑term margin recovery.

Extremely Lean Operating StructureA very small headcount implies low fixed operating overhead and a lean cost base, which structurally extends runway per capital raised and enables flexible outsourcing or partner‑led commercialization. This conserves cash while management advances regulatory and partnering milestones.

Bears Say

Heavy Cash BurnSustained large negative operating cash flow and material free‑cash burn create a structural need for external financing within months. That reliance increases dilution or debt issuance risk, pressures milestone pacing, and constrains the company’s ability to fund trials or commercialization without partner transactions.

Very High LeverageA sharp shift to meaningful debt on a tiny equity base produces elevated solvency and refinancing risk. High leverage reduces strategic flexibility, increases interest burden and could force unfavorable financing terms or expedited partnering to shore up the balance sheet over the next several months.

Minimal Revenue And Large LossesNear‑zero recurring revenue paired with very large net losses signals pre‑commercial status and limited internal funding. The sharp revenue contraction and negative margins mean operational sustainability depends on clinical/regulatory progress or external deals, increasing execution risk over the medium term.

8LY FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was €0.45 and its highest was €0.75 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is €9.64M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is Aug 27, 2026 which is in 68 days.

How were OncoZenge AB’s earnings last quarter?

OncoZenge AB released its earnings results on May 20, 2026. The company reported -€0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.05.

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 14,048,068 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

OncoZenge AB reported an EPS of -€0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.407%.

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in DE:8LY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).